NOVA Stock Overview
Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Nova Mentis Life Science Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.07 |
| 52 Week Low | CA$0.01 |
| Beta | 0.69 |
| 1 Month Change | 0% |
| 3 Month Change | -25.00% |
| 1 Year Change | -78.57% |
| 3 Year Change | -87.50% |
| 5 Year Change | -97.50% |
| Change since IPO | -99.94% |
Recent News & Updates
Shareholder Returns
| NOVA | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 50.0% | 0.4% | 0.7% |
| 1Y | -78.6% | -37.2% | 4.9% |
Return vs Industry: NOVA underperformed the Canadian Biotechs industry which returned -38.2% over the past year.
Return vs Market: NOVA underperformed the Canadian Market which returned 5.5% over the past year.
Price Volatility
| NOVA volatility | |
|---|---|
| NOVA Average Weekly Movement | 44.7% |
| Biotechs Industry Average Movement | 13.3% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: NOVA's share price has been volatile over the past 3 months.
Volatility Over Time: NOVA's weekly volatility has increased from 31% to 45% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Will Rascan | www.novamentis.ca |
Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. The comapny engages in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome. It has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay.
Nova Mentis Life Science Corp. Fundamentals Summary
| NOVA fundamental statistics | |
|---|---|
| Market cap | CA$2.22m |
| Earnings (TTM) | -CA$1.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs NOVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVA income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$1.22m |
| Earnings | -CA$1.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NOVA perform over the long term?
See historical performance and comparison